The effects of pregabalin on neuropathic pain relief and the serum visfatin level were assessed using an experimental model of neuropathy in a study conducted on 40 male mice with sciatic nerve constriction. The mice were randomly assigned to 4 groups, each with 10 mice. The mice were subjected to experimental chronic partial constriction of the sciatic nerve and compared to sham-operated, saline-treated control mice (group I). The experimental groups (II-IV) were subjected to partial constriction of the left sciatic nerve. A series of behavioral tests, electrophysiological studies and biochemical measures were performed after 3 weeks of daily oral treatment with pregabalin (20 and 40 mg/kg in groups III and IV, respectively). The study revealed the actions of pregabalin against the nociceptive effects of chronic sciatic nerve constriction in mice (p < 0.01), including replenishment of the glutathione level (p < 0.05) and reduction of the serum visfatin level. No significant effect on the tissue malondialdehyde level was found for any of the pregabalin doses. The percentage differences in the maximum tetanic force between the ipsilateral and contra lateral legs were significant in both pregabalin-treated groups (p < 0.05). We concluded that pregabalin reduced the serum visfatin level and produced a dose-dependent antinociceptive antioxidant effect.

1.
Vinik A: Clinical review: use of antiepileptic drugs in the treatment of chronic painful diabetic neuropathy. J Clin Endocrinol Metab 2005;90:4936-4945.
2.
Bosnjak S, Jelic S, Susnjar S, Luki V: Gabapentin for relief of neuropathic pain related to anticancer treatment: a preliminary study. J Chemother 2002;14:214-219.
3.
Xiao W, Boroujerdi A, Bennett GJ, Luo ZD: Chemotherapy-evoked painful peripheral neuropathy: analgesic effects of gabapentin and effects on expression of the alpha-2-delta type-1 calcium channel subunit. Neuroscience 2007;144:714-720.
4.
Chen MP, Chung FM, Chang DM, Tsai JC, Huang HF, Shin SJ, Lee YJ: Elevated plasma level of visfatin/pre-B cell colony-enhancing factor in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 2006;91:295-299.
5.
Moschen AR, Kaser A, Enrich B, Mosheimer B, Theurl M, Niederegger H, Tilg H: Visfatin, an adipocytokine with proinflammatory and immunomodulating properties. J Immunol 2007;178:1748-1758.
6.
Łuszczki JJ: Dose-response relationship analysis of pregabalin doses and their antinociceptive effects in hot-plate test in mice. Pharmacol Rep 2010;62:942-948.
7.
Lee BH, Won R, Baik EJ, Lee SH, Moon CH: An Animal model of neuropathic pain employing injury to the sciatic nerve branches. Neuroreport 2000;11:657-661.
8.
Le Bars D, Gozariu M, Cadden SW: Animal models of nociception. Pharmacol Rev 2001;53:597-652.
9.
Randall LO, Selitto JJ: A method for measurement of analgesic activity on inflamed tissue. Arch Int Pharmacodyn Ther 1957;111:409-419.
10.
Choi Y, Yoon YW, Na HS, Kim SH, Chung JM: Behavioral signs of ongoing pain and cold allodynia in rat model of neuropathic pain. Pain 1994;59:369-376.
11.
Schertzer JD, Plant DR, Lynch GS: Optimizing plasmid-based gene transfer for investigating skeletal muscle structure and function. Mol Ther 2006;13:795-803.
12.
Ellman GL: Tissue sulfhydryl groups. Arch Biochem Biophys 1959;82:70-77.
13.
Ohkawa H, Ohishi N, Yagi K: Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem 1979;95:351-358.
14.
Haider DG, Schaller G, Kapiotis S, Maier C, Luger A, Wolzt M: The release of the adipocytokine visfatin is regulated by glucose and insulin. Diabetologia 2006;49:1909-1914.
15.
Newton RA, Bingham S, Case PC, Sanger GJ, Lawson SN: Dorsal root ganglion neurons show increased expression of the calcium channel alpha2delta-1 subunit following partial sciatic nerve injury. Brain Res Mol Brain Res 2001;95:1-8.
16.
Narciso MS, Mietto Bde S, Marques SA, Soares CP, Mermelstein Cdos S, El-cheikh MC, Martinez AM: Sciatic nerve regeneration is accelerated in galectin-3 knockout mice. Exp Neurol 2009;217:7-15.
17.
Field MJ, Bramwell S, Hughes J, Singh L: Detection of static and dynamic components of mechanical allodynia in rat models of neuropathic pain: are they signalled by distinct primary sensory neurones? Pain 1999;83:303-311.
18.
Buys MJ, Alphonso C: Novel use of perineural pregabalin infusion for analgesia in a rat neuropathic pain model. Anesth Analg 2014;119:481-488.
19.
Chen SR, Xu Z, Pan HL: Stereospecific effect of pregabalin on ectopic afferent discharges and neuropathic pain induced by sciatic nerve ligation in rats. Anesthesiology 2001;95:1473-1479.
20.
Celik M, Kose A, Kose D, Karakus E, Akpinar E, Calik M, Dostbil A, Calikoglu C, Aksoy M, Ozel L: The double-edged sword: effects of pregabalin on experimentally induced sciatic nerve transection and crush injury in rats. Int J Neurosci 2014, Epub ahead of print.
21.
Whitlock EL, Moradzadeh A, Hunter DA, Mackinnon SE: Pregabalin does not impact peripheral nerve regeneration after crush injury. J Reconstr Microsurg 2007;23:263-268.
22.
Kale A, Börcek AÖ, Emmez H, Yildirim Z, Durdağ E, Lortlar N, Kurt G, Doğulu F, Kılıç N: Neuroprotective effects of gabapentin on spinal cord ischemia-reperfusion injury in rabbits. J Neurosurg Spine 2011;15:228-237.
23.
Sills GJ: The mechanisms of action of gabapentin and pregabalin. Curr Opin Pharmacol 2006;6:108-113.
24.
Harvey VL, Dickenson AH: Behavioural and electrophysiological characterisation of experimentally induced osteoarthritis and neuropathy in C57Bl/6 mice. Mol Pain 2009;5:18.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.